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Background: National guidelines recommend screening patients with thoracic cancer to iden-
tify those requiring nutritional support. To help quantify this area of need, the associated
workload and explore its impact, we report findings from a dedicated rehabilitation service.
Methods: Patients were screened soon after diagnosis to determine the prevalence of malnu-
trition, and various aspects compared between malnourished and not malnourished groups. A
nutritional care plan was instigated and all contacts recorded, together with follow-up body
weight.
Results: Of 243 patients seen, 35% were malnourished which was associated with a palliative
treatment intent (P < 0.05) and a reduced survival (median 155 days less, 1-year survival
19% vs. 41%; P < 0.01 for both); nonetheless, for about one-fifth, treatment intent was cura-
tive. Overall, about two-thirds of patients were failing to meet their daily recommended en-
ergy intake. The dietitian provided over 870 episodes of care, a median of three per patient.
More of the malnourished group received oral nutritional supplements, but also experienced
problems tolerating them. Over one month, neither the pattern nor magnitude of the change
in weight differed between malnourished and not malnourished groups. Overall, weight was
stable, increased or decreased in 52 (27%), 80 (42%) and 59 (31%) respectively, with no differ-
ence in overall survival (P Z 0.16).use Specialist Palliative Cancer Care Unit, Nottingham University Hospitals NHS Trust, Nottingham NG5
fax: þ44 (0) 115 962 7779.
ottingham.ac.uk (A. Wilcock).
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754 C. Percival et al.Conclusion: Our data provides a pragmatic insight into the implications of following national
guidance on nutritional screening and support in this patient group. Nutritional support failed
to prevent weight loss in some patients, and did not appear to impact on survival; new assess-
ments and treatments for cachexia are required.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Weight loss is a common feature of thoracic cancer, asso-
ciated with increased morbidity, poorer treatment toler-
ability and outcomes, and reduced survival, in both
extensive and limited disease.1e6 It occurs in the context of
cancer cachexia, where a variable combination of reduced
food intake and abnormal metabolism leads to a negative
protein and energy balance, resulting in the loss of skeletal
muscle (fat) mass.7
The metabolic abnormalities in cachexia are thought to
explain the generally disappointing response to nutritional
support alone.8,9 Nonetheless, various national and spe-
cialty guidelines recommend screening all patients gen-
erally, and cancer patients specifically, to identify those
who are malnourished or have an inadequate intake for
further dietetic assessment and nutritional support, with
the aim of preventing or slowing further weight loss.10e12
Such an approach also forms an integral part of a recently
developed rehabilitation care pathway for patients with
lung cancer.13 Despite these recommendations, not all
cancer services have such an approach in place, and the
nutritional needs of patients may go unmet.
Locally, Macmillan Cancer Support have funded a proac-
tive multidisciplinary rehabilitation service (MRS) dedi-
cated to patients with thoracic cancer. In addition to an
occupational therapist and physiotherapist, there is one
full-time dietitian which allows the provision of nutritional
support in accordance with national guidance. Here we
report our pragmatic experience over one year with regards
to the nutritional support needs, the associated dietetic
workload and exploration of its impact in this group of
patients.
Methods
Identification of patients
Over 400 patients are diagnosed with thoracic cancer each
year by the comprehensive thoracic oncology service at
Nottingham University Hospitals NHS Trust, which includes
a supra-regional thoracic surgical unit. The lung cancer
nurse specialists (LCNS) attend the Lung Cancer Multi-
disciplinary Team meetings and identified patients with
a new diagnosis of thoracic cancer potentially suitable to
be seen by the MRS, i.e. those residing within the hospital’s
main catchment area, who were well enough to be assessed
and agreed to be approached. These patients were high-
lighted at the weekly MRS meeting attended by the LCNS. In
keeping with national guidance on holistic assessment,14,15
patients were invited to complete the 45-item Sheffield
Profile for Assessment and Referral to Care (SPARCª)
questionnaire.16 This is an acceptable means of undertakingan assessment of supportive and palliative care needs in
this group of patients.17 According to patient preference, it
was completed either at a hospital visit, or posted out with
a return envelope. The responses were subsequently
reviewed at the MRS meeting and, according to the needs
identified, the appropriate team member(s) made contact
for further assessment and intervention. All were offered
a dietetic assessment by the MRS dietitian (CP). The time to
first assessment was mainly dependent on how quickly
a SPARCª questionnaire was obtained; most patients were
seen within three weeks and no later than six weeks fol-
lowing receiving their diagnosis.
As a clinical service undertaking assessments and pro-
viding care in line with national recommendations, formal
ethics committee approval was not considered necessary.18Dietetic assessment
Various aspects of the dietetic assessment were recorded
onto a clinical dataset:
Demographic details: Age, sex, type and stage of
thoracic cancer, co-morbidities which may affect dietary
intake, Eastern Cooperative Oncology Group (ECOG) per-
formance status, treatment planned or received (curative
or palliative intent). Weight was recorded using patients
own scales or, when unavailable, portable scales (Seca
medical scales, model 877, Hamburg, Germany). Height
was generally patient-reported.
Identification of patients who are malnourished: Based
on nationally recommended definition and criteria, i.e.
a state of nutrition in which a deficiency of energy, protein
and/or other nutrients causes measurable adverse effects
on tissue/body form, composition, function or clinical
outcome; considered likely significant when body mass
index (BMI) <18.5 kg/m2, weight loss >10%, or BMI <20 kg/
m2 and weight loss >5%.10
Identification of patients who are at risk of malnu-
trition: Based on nationally recommended criteria, i.e.
having any of the following: eaten little or nothing for >5
days and/or are likely to eat little or nothing for the
next 5 days; poor absorptive capacity; high nutrient los-
ses, or increased nutritional needs from causes such as
catabolism.10
Nutritional intake: Protein and energy intake calculated
using Compeat (version 5.8.0, Nutrition Systems, Gran-
tham, UK) based on 24 h recall and compared to the ref-
erence nutrient intake (RNI)19; current use of prescribed
oral nutritional supplements (ONS).
The full dietetic assessment was more comprehensive,
exploring factors which may affect nutritional intake, i.e.
the ability to obtain or prepare meals, meal pattern and the
presence of symptoms such as anorexia, nausea and vom-
iting and constipation.
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Information from the dietetic assessment together with the
patient’s likely prognosis were used to develop an individu-
alized nutritional care plan. All received dietetic counselling,
supported by written materials. In those considered to have
a reasonable prognosis (i.e. 2e3 months or more), the aim of
dietetic counselling was to optimize intake with high protein
and energy foods, while ensuring an adequate intake of other
nutrients and micronutrients. Eating was encouraged and
advice provided on dietary fortification, use of snacks and
how to overcome specific eating difficulties, e.g. anorexia or
others related to the cancer or its treatment. Oral nutritional
supplements (ONS) were offered to those who were mal-
nourished, or at risk ofmalnutrition, e.g. failing tomeet their
RNI, considered unlikely to sufficiently improve their intake
though dietary measures alone. Fortisip, Fortijuce,
Scandishake and Calogen Extra were the most frequently
used products reflecting their availability on the local for-
mulary.When patients were considered to be in their last few
weeks of life, dietetic counselling focused on food and drink
as a pleasure to be enjoyed as able, rather than aiming to
meet a set minimum intake. Consequently, ONS were used
less in this group of patients.
Patients were followed up at least monthly to ensure
that the objectives of their nutritional care plan were being
met, with all dietetic contact routinely recorded using
Clinical Manager SQL (Version 5, Streets Heaver Healthcare
Computing, Lincoln, UK). Patients were instructed to weigh
themselves using the same scales, wearing similar clothing
at about the same time of day. For changes of 0.5 kg or less,
weight was considered stable.
Statistical analysis
Data is presented as mean (SD) or median [interquartile
range, IQR] as appropriate. Student’s T, ManneWhitney U
tests of difference, or Pearson’s chi-squared test were used
as appropriate to compare for differences between pa-
tients identified as malnourished and those not. Kaplan and
Meier survival curves were compared using the log-rank
test. All calculations were performed using Statistical
Package for the Social Sciences (version 17) and a P value of
<0.05 was considered statistically significant.Figure 1 Patient flow.Results
Patient flow and demographics
Between 1st October 2009 and 30th September 2010,
a total of 414 patients reviewed by the Lung Cancer Mul-
tidisciplinary Team had either a histological (85%) or clinical
diagnosis of thoracic cancer, with 365 considered poten-
tially appropriate for the MRS by the LCNS. Of these, 19
died before being discussed at the weekly MRS meeting. Of
the remaining 346 invited to complete an SPARCª ques-
tionnaire, the MRS subsequently saw 287 at least once, with
243 (85%) of these undergoing a full dietetic assessment
(Fig. 1). Demographic and other details of these 243 pa-
tients are summarized in Table 1.Dietetic assessment
Based on nationally recommended criteria, 84 (35%) pa-
tients were malnourished to an extent that warranted
consideration of nutritional support (Table 1). Compared to
those not malnourished, malnourished patients were less
likely to be treated with a curative intent (30% vs. 18%;
P < 0.05); there were no other differences in respect of
gender, age, performance status, type of thoracic cancer or
stage (Table 1). As of 30th September 2011, 68 (81%) and 94
(59%) of those malnourished and not malnourished respec-
tively had died. Median overall survival and 1-year survival
rates were significantly lower in the malnourished group, at
155 days less (P < 0.01; Table 1) and 19% vs. 41% (P < 0.01)
respectively, with the survival curves for the two groups
showing clear separation (Fig. 2).
Comparison of patients who were malnourished with
those who were not revealed significant differences in
weight, BMI and % weight loss as expected, along with daily
intake of energy and protein, and proportion failing to meet
the RNI for protein (35 vs. 20%; P Z 0.01) (Table 1). How-
ever, similar proportions of patients in either group were
failing to meet their daily RNI for energy (71 vs. 64%;
PZ 0.25). Only three patients (1%) were already using ONS
which suggests that the nutritional needs of this group are
Table 1 Demographic, nutritional and other details of the 243 patients who underwent dietetic assessment.
Total Not malnourished Malnourished P value
Number (%) 243 (100) 159 (65) 84 (35)
Gender: male, n (%) 139 (57) 92 (58) 47 (56) 0.78
Mean (SD) age, years 70 (10) 70 (9) 71 (11) 0.92
Performance status (ECOG), n (%) 0.25a
0 62 (26) 45 (28) 17 (20)
1 67 (28) 50 (31) 17 (20)
2 43 (18) 26 (16) 17 (20)
3 45 (19) 22 (14) 23 (27)
4 4 (2) 1 (1) 3 (3)
Missing 22 (9) 15 (9) 7 (8)
Type of thoracic cancer, n (%) 0.11a
NSCLC 187 (77) 127 (80) 60 (71)
SCLC 32 (13) 16 (10) 16 (10)
Clinical diagnosis 14 (6) 8 (5) 6 (7)
Mesothelioma 10 (4) 8 (5) 2 (2)
Stage, n (%)
NSCLC and clinical diagnosis 0.17a
I 30 (12) 25 (16) 5 (6)
II 26 (11) 16 (10) 10 (12)
III 52 (21) 36 (23) 16 (19)
IV 93 (38) 58 (36) 35 (42)
SCLC and mesothelioma 0.65a
Local 8 (3) 4 (3) 4 (5)
Extensive 34 (14) 20 (13) 12 (17)
Planned/current treatment, n (%) 0.07a
Surgery 59 (24) 44 (27) 15 (18)
Chemotherapy 79 (33) 52 (33) 27 (32)
Radiotherapy 43 (18) 27 (17) 16 (19)
Chemotherapy þ radiotherapy 11 (5) 7 (4) 4 (5)
Palliative care 33 (14) 16 (10) 17 (20)
Watch and wait 10 (4) 8 (5) 2 (2)
Declined or died before treatment 8 (13) 5 (3) 3 (4)
Treatment intent, n (%) <0.05a
Curative 62 (26) 47 (30) 15 (18)
Palliative 181 (74) 112 (70) 69 (82)
Survival
Days 288 [140e479] 368 [157e507] 213 [110e383] <0.01
At one year, n (%) 81 (33) 65 (41) 13 (19) <0.01
Mean (SD) weight, kg 69.8 (15) 72.2 (14) 62.9 (15) <0.01
Mean (SD) height, m 1.67 (0.10) 1.68 (0.10) 1.67 (0.10) 0.85
Number with:
BMI <18.5 kg/m2 19 0 19 e
Weight loss >10% 59 0 59 e
BMI <20 kg/m2 and weight loss >5% 6 0 6 e
BMI kg/m2 24 [21e27] 25 [22e28] 22 [19e25] <0.01
% Weight loss 5 [0e11] 2 [0e6] 14 [10e17] <0.01
Protein intake g/day 72 [53e87] 75 [54e93] 63 [47e82] <0.01
Failing to meet RNI, n (%) 61 (25) 32 (20) 29 (35) 0.01
Energy intake (kCal/day) 1831 [1448e2163] 1919 [1555e2193] 1647 [1321e2101] <0.01
Failing to meet RNI, n (%) 167 (67) 102 (64) 60 (71) 0.25
ONS use, n (%) 3 (1) 3 (2) 0 (0) e
Values are median [IQR] unless specified otherwise. ECOG, Eastern Cooperative Oncology Group; NSCLC, non-small cell lung cancer;
SCLC, small cell lung cancer; BMI, body mass index; RNI, reference nutrient intake; ONS, oral nutritional supplement.
a Pearson’s chi-squared test.
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Figure 2 Survival curves for malnourished and not malnour-
ished patients. Median survival was 155 days less in the mal-
nourished group (P < 0.01).
Nutritional support in thoracic cancer 757not routinely identified elsewhere, e.g. by the primary care
team.
If accepted that all patients with thoracic cancer meet
the national guideline criteria of increased nutritional
needs because of catabolism,7,10 then all of the not mal-
nourished group could be considered at risk of malnutrition.
Applying the remaining criteria identified only one patient
at risk of malnutrition, based on them eating little or
nothing (arbitrarily defined as <600 kCal/day).Dietetic workload
Over the 12 month period, working full time, the dietitian
provided 874 (243 new and 631 follow-up) separateTable 2 Intervention and change in weight after one month ac
Not malnourished
Number 130
Intervention
Counselling, n (%) 94 (72)
Counselling þ ONS, n (%) 36 (28)
Unable to tolerate ONS, n (%) 2 (6)
Weight
Gained, n (%) 30 (23)
Median [IQR], kg 2.2 [1.0e4.6]
Median [IQR] % 3 [2e6]
Stableb, n (%) 60 (46)
Lost, n (%) 40 (31)
Median [IQR], kg 3.3 [1.7 to 4
Median [IQR] % 5 [3 to 6]
ONS, oral nutritional supplements.
a Pearson’s chi-squared test.
b Defined as within 0.5 kg of baseline weight.episodes of care. This included 403 face-to-face contacts
and 471 telephone contacts, with 85% of new reviews and
9% of follow-up visits undertaken in the patient’s home.
Most follow-up contacts (75%) were by telephone. The
median [IQR] number of contacts per patient was 3 [25]. A
first assessment would generally take 12 h, follow-up
home visit 11.5 h, and follow-up review by telephone
0.5 h with these times including associated travel and
administration.
Outcomes
The number of patients rapidly declined with each month
of follow-up, i.e. 191, 128, 78, 39 and 10, due mainly to
deterioration, death or further dietetic input being
declined. Reasons for the latter ranged between being
satisfied with current intake and/or weight, and not
wanting to continue with ONS. Thus, outcome data for 191
patients after one month were analyzed, representing 79%
of those originally assessed (Fig. 1). Reasons for the 52
patients dropping out within the first month, included
death (18), being in the last days of life (15) and declining
further dietetic support because of being satisfied with
progress (13) or without giving reason (6).
Overall, 108 (57%) of these patients received counselling
alone and the remainder counselling and ONS (Table 2).
Compared to the not malnourished group, more in the
malnourished group received ONS (77% vs. 28%, P < 0.01)
but also discontinued them because of difficulties in tol-
erating them (28% vs. 6%, P < 0.01). After one month,
overall, weight was gained, stable or lost in 52 (27%), 80
(42%) and 59 (31%) patients respectively; corresponding
median [IQR] survival was 205 [144e266], 326 [250e402]
and 213 [149e277] days, which did not differ significantly
(P Z 0.16). Neither the pattern, nor the magnitude of the
absolute or percentage change in weight differed between
the malnourished and not malnourished groups (Table 2).
Differences were also sought in the malnourished and
not malnourished groups separately between patients who
had gained, maintained or lost weight and demographic andcording to nutritional status.
Malnourished P value
61
<0.01a
14 (23)
47 (77)
13 (28) <0.01a
22 (36) 0.06
2.0 [1.3e5.3] 0.70
4 [2e8] 0.18
20 (33) 0.08
19 (31) 0.96
.9] 3.0 [2.0 to 5.0] 0.69
6 [3 to 7] 0.16
758 C. Percival et al.other details (Table 3). In the malnourished group, age
differed such that patients who gained weight rather than
stabilized or lost it were younger (mean age 68 vs. 71 vs. 71
years respectively; P Z 0.04); a similar non-significant
trend was also seen in the not malnourished group. In the
not malnourished group, the type of cancer differed, such
that a higher proportion of patients with SCLC gainedTable 3 Relationship between change in weight after one mon
Not malnourished (n Z 130)
Gained Stableb Lost
Number (%) 30 (23) 60 (46) 40 (31)
Intervention, n (%)
Counselling 23 (77) 43 (72) 28 (70)
Counselling þ ONS 7 (23) 17 (28) 12 (30)
Unable to tolerate ONS 0 (0) 2 (3) 0 (0)
Male: female, n (%) 17 (57):
13 (43)
35 (58):
25 (42)
25 (63)
15 (37)
Mean (SD) age, years 67 (11) 72 (8) 72 (8)
Performance status
(ECOG) n (%)
0 10 (33) 16 (27) 11 (28)
1 8 (27) 24 (40) 15 (38)
2 5 (17) 6 (10) 7 (18)
3 5 (17) 8 (13) 4 (10)
Missing 2 (7) 6 (10) 3 (8)
Type of thoracic
cancer, n (%)
NSCLC 18 (60) 50 (83) 35 (88)
SCLC 8 (27) 4 (7) 2 (5)
Mesothelioma 1 (3) 5 (8) 3 (7)
Clinical diagnosis 3 (10) 1 (2) 0
Stage, n (%)
NSCLC
I 4 (13) 11 (18) 6 (15)
II 2 (6) 7 (12) 2 (5)
III 8 (27) 9 (14) 13 (32)
IV 5 (17) 28 (47) 14 (35)
SCLC and mesothelioma
Local 3 (10) 1 (2) 0
Extensive 8 (27) 4 (7) 5 (13)
Planned/current
treatment, n (%)
Surgery 9 (30) 13 (22) 17 (43)
Chemotherapy 15 (50) 18 (3) 13 (32)
Radiotherapy 1 (3) 14 (23) 8 (20)
Chemotherapy þ
radiotherapy
2 (7) 2 (3) 1 (3)
Palliative care 3 (10) 5 (8) 1(3)
Watch and wait 0 7 (12) 0
Declined or died
before treatment
0 1 (2) 0
Treatment intent, n (%)
Curative 8 (27) 17 (28) 15 (38)
Palliative 22 (73) 43 (72) 25 (62)
ECOG, Eastern Cooperative Oncology Group; NSCLC, non-small cell
supplements.
a Pearson’s chi-squared test.
b Defined as within 0.5 kg of baseline weight.weight rather than stabilized or lost it (27% vs. 7% vs. 5%
respectively; PZ 0.01). However, numbers of patients with
SCLC in each group were small (8). Current treatment also
differed in both groups (PZ 0.03), but small numbers limit
meaningful interpretation (Table 3). There were no other
differences in gender, performance status, stage or treat-
ment intent in either group (Table 3).th and various demographic and disease aspects (n Z 191).
Malnourished (n Z 61)
P Gained Stableb Lost P
22 (37) 20 (33) 19 (32)
0.81a 0.29a
4 (18) 7 (35) 3 (16)
18 (82) 13 (65) 16 (84)
5 (23) 2 (10) 6 (32)
: 0.87 13 (59):
9 (41)
10 (50):
10 (50)
9 (47):
10 (53)
0.98
0.06 68 (11) 71 (11) 71 (8) 0.04
0.93a 0.70a
9 (41) 3 (15) 2 (11)
7 (32) 5 (25) 2 (11)
2 (9) 6 (30) 5 (26)
3 (14) 5 (25) 6 (32)
1 (5) 1 (5) 4 (21)
0.01a 0.30a
15 (68) 18 (90) 10 (53)
5 (22) 2 (10) 6 (32)
1 (5) 0 2 (11)
1 (5) 0 1 (5)
0.21a 0.73a
3 (14) 1 (5) 1 (5)
4 (18) 2 (10) 2 (11)
2 (9) 7 (35) 1 (5)
7 (32) 8 (40) 8 (42)
0.44a 0.79a
0 1 (5) 2 (11)
6 (27) 1 (5) 5 (26)
0.03a 0.03a
8 (36) 2 (10) 3 (16)
8 (36) 6 (30) 9 (47)
6 (28) 3 (15) 3 (16)
0 3 (15) 0
0 6 (30) 3 (16)
0 0 1 (5)
0 0 0
0.53a 0.26a
7 (32) 5 (25) 2 (11)
15 (68) 15 (75) 17 (89)
lung cancer; SCLC, small cell lung cancer; ONS, oral nutritional
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When providing nutritional support in line with national
recommendations to patients with a recent diagnosis of
thoracic cancer in a ‘real-world’ setting, our main findings
are that: a) 35% are malnourished; b) malnutrition is asso-
ciated with a reduced survival; c) many of those who are
deemed not malnourished based on the screening criteria,
are failing to meet their recommended daily intake of en-
ergy and protein; d) weight gain or stabilization can occur
in the short-term, irrespective of initial nutritional status,
but is not related to a difference in survival, and e) 31%
continue to lose weight despite nutritional support. Our
data also provides an indication of the associated dietetic
workload.
This is the largest cohort arising from an attempt to
systematically screen consecutive patients newly present-
ing with thoracic cancer. A prevalence of malnutrition of
35% confirms the findings of our previous smaller survey.20
Wider comparison is limited by differing methodology, but
others report significant weight loss (>10%) in 14e43% of
patients in various settings.2,21,22 It is of note that malnu-
trition is not limited to those with advanced disease, with
one-fifth being considered for, or receiving treatment with
curative intent.
Despite identifying patients soon after diagnosis, about
one-third were not seen by the dietitian. This was mainly
due to patients dying, or being close to death and un-
derscores the often late presentation of patients with
thoracic cancer. In those assessed, we found malnutrition
to be associated with reduced survival, as reported by
others.1e6 Direct comparison of survival is limited, as pre-
vious analyses were restricted to various subgroups of pa-
tients, or stratified by performance status and/or degree of
weight loss. Given the difference in treatment intent, our
data suggests that in part it relates to the stage of the
disease.
There is no universally agreed gold standard method of
screening patients to identify those who are malnourished
or at risk of malnutrition. We used the National Institute for
health and Clinical Excellence guidelines which are simple,
permitting any health professional to identify malnourished
patients and refer them for nutritional support.10 However,
they appeared less helpful in identifying patients at risk of
malnutrition, as most of the criteria failed to identify the
majority of our patients not meeting their daily RNI of en-
ergy or protein. This suggests that all patients with thoracic
cancer should be routinely referred for dietetic assess-
ment. Other nutritional screening and assessment tools are
available, some of which have been developed for, or used
in patients with cancer, which may provide a more dis-
criminatory approach.23e25 However, this would require
formal comparison and longer completion times are a po-
tential disadvantage. All are lacking from a cachexia per-
spective, with a direct assessment of skeletal muscle tissue
considered the ideal.7,26
Our findings reflect the lack of evidence of survival
benefit from nutritional support in cancer cachexia and
other causes of disease-related malnutrition.7e9,2731 Even
when the aim of nutritional support is to prevent or slow
further weight loss,1012 this appears unlikely to translate
into a meaningful effect on survival, unless the underlyingmetabolic abnormalities primarily responsible for the loss
of skeletal muscle, the hallmark of cachexia, are also
addressed.7 We found weight to increase or stabilize in
about two-thirds of patients. Although nutritional support
to patients with disease-related malnutrition of various
aetiologies has been found to improve weight, body com-
position and grip strength,30 no such benefit was evident in
a recent review and meta-analysis which was limited to
patients with cancer.9 Nonetheless, there were other ben-
efits from nutritional support in patients with cancer, with
improvement seen in some aspects of quality of life9;
however, as we did not assess quality of life we are unable
to explore this. Other limitations which need to be con-
sidered when interpreting our findings include the uncon-
trolled nature of the intervention, the short duration of
follow-up, a lack of body composition analysis and consid-
eration of other potentially relevant factors, e.g. response
of the cancer to first-line treatment, systemic inflammation
and hypogonadism. Although a randomized, controlled trial
is the ideal, this could present ethical challenges given
current guidance on nutritional support.10e12 However,
their reliance on consensus statements and good practice
points due to a lack of high quality RCT evidence has been
highlighted.9 Relating weight and changes in weight to body
composition is important. Severe muscle depletion, con-
sidered the most relevant from a prognostic and functional
perspective, can be present irrespective of BMI and, com-
pared to fat mass, is less likely to improve with nutritional
support.7,31,32 We did not assess systemic inflammation,7
nor endocrine factors such as hypogonadism, which was
found in three-quarters of male patients referred to
a cachexia clinic.33 Nonetheless, having benchmarked this
approach, changes can be made and outcomes re-
examined. For example, we plan to introduce the use of
fish-oils which have shown recent promise in patients with
lung cancer, helping to maintain skeletal muscle mass and
body weight.34,35
New treatments for cachexia are required and several
are in development.36 Nonetheless, nutritional support
is likely to remain an important component of its manage-
ment. Thus, research is also required to examine
the challenges faced in its provision, such as symptoms
limiting intake (e.g. anorexia, early satiety)33 and ways of
enhancing compliance with ONS, particularly as one-
quarter of malnourished patients were unable to tolerate
them.
In conclusion, malnutrition, as defined in national
guidelines, is common in patients newly diagnosed with
thoracic cancer, even in those with potentially curative
disease, and is associated with a reduced survival. A routine
dietetic assessment is required to reliably identify those
patients at risk of malnutrition, for whom nutritional sup-
port is also recommended. This has implications for dietetic
services, and our experience gives an indication of the
associated workload. Nonetheless, nutritional support
represents only one aspect of the management of cachexia
and the exact benefits of its routine provision from the time
of diagnosis are uncertain. Increased understanding of the
pathophysiology of cachexia has highlighted the need for
a more specific assessment of skeletal muscle mass,
together with new treatments which address the underlying
abnormal metabolism.
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